STOCK TITAN

Abbott extends executive agreements, excluding CEO

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Abbott Laboratories (ABT) notified its named executive officers, other than Chairman of the Board and Chief Executive Officer Robert B. Ford, on November 11, 2026 that the terms of their change-in-control agreements were extended through December 31, 2028. Ford’s agreement will expire on December 31, 2026.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Extended agreement term Through December 31, 2028 Terms extended for named executive officers other than Robert B. Ford
Robert B. Ford agreement expiration December 31, 2026 Chairman of the Board and Chief Executive Officer
Agreements Regarding Change in Control technical
"Agreements Regarding Change in Control"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How could Abbott extend the ABT change-in-control agreements?

The agreements provide that if Abbott gives notice of extension before the December 31, 2026 expiration date, their terms continue through the second anniversary of that date. Abbott notified the named executive officers other than Robert B. Ford on November 11, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0000001800 Common Shares, Without Par Value ABT 0000001800 2026-11-11 2026-11-11 0000001800 us-gaap:CommonStockMember exch:XCHI 2026-11-11 2026-11-11 0000001800 us-gaap:CommonStockMember exch:XNYS 2026-11-11 2026-11-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
   
Chicago Stock Exchange, Inc. [Member]      

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

November 11, 2026

Date of Report (Date of earliest event reported)

 

ABBOTT LABORATORIES

(Exact name of registrant as specified in charter)

 

 

 

Illinois   1-2189   36-0698440
(State or other Jurisdiction   (Commission File Number)   (IRS Employer
of Incorporation)       Identification No.)

 

 

 

100 Abbott Park Road

Abbott Park, Illinois 60064-6400

(Address of principal executive offices)(Zip Code)

 

Registrant’s telephone number, including area code:  (224) 667-6100

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities Registered Pursuant to Section 12(b) of the Act:

 

Title of Each Class Trading
Symbol(s)

Name of Each Exchange on
Which Registered

Common Shares, Without Par Value ABT

New York Stock Exchange

Chicago Stock Exchange, Inc.

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

As previously reported, Abbott has Agreements Regarding Change in Control (“Agreements”) with its named executive officers.

 

The Agreements provide that if Abbott gives notification of extension before the Expiration Date (December 31, 2026), the Agreement’s term shall continue through the second anniversary of the Expiration Date.

 

On November 11, 2026, Abbott notified the named executive officers, other than Robert B. Ford, Abbott’s Chairman of the Board and Chief Executive Officer, that the term of the Agreements was extended through December 31, 2028. Mr. Ford’s Agreement will expire on December 31, 2026.

 

   

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ABBOTT LABORATORIES
   
Date: November 13, 2026 By: /s/ Philip P. Boudreau
  Philip P. Boudreau
  Executive Vice President, Finance and Chief Financial Officer

 

   

 

Filing Exhibits & Attachments

4 documents

Keep reading